Treats overactive bladder with symptoms of urge urinary incontinence, urgency, and…. ANDA 204374, held by Macleods Pharms. Solifenacin Succinate.
As of Nov 16, 2026, ANDA 204374 (Solifenacin Succinate), held by Macleods Pharms, was first approved by FDA on Feb 20, 2024, with 0 approved supplements and 0 published complete response letters.
Solifenacin succinate tablets are indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 20, 2024 | Original application | Approved | None posted |
| Solifenacin Succinate5MG · tablet;oral | Solifenacin Succinate | Rx |
| Solifenacin Succinate10MG · tablet;oral | Solifenacin Succinate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters